Drug intelligence / Profile preview

QGB-01

Development stage: Preclinical
Lead developer: AceMapAI Biotechnology

Overview

QGB-01 is a preclinical drug candidate developed by AceMapAI Biotechnology (also known as QureGenAI), an AI-driven drug discovery company focusing on aging-related diseases and oncology. As of the latest pipeline update, QGB-01 is categorized as PCC Ready (Preclinical Candidate Ready), indicating it has completed early discovery and lead optimization phases. Due to its early stage of development and the proprietary nature of the company's discovery platform, specific details regarding its biological target, therapeutic modality, and primary disease indications have not been publicly disclosed.

Beyond the preview

Go deeper on QGB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QGB-01.

Explore the full profile